

**Freedom of Information Request****Ref: UHB 18-178**

Date 20 April 2018

By Email

Dear Sir

Thank you for your request for information under the Freedom of Information Act 2000. The Trusts response is as follows:

- 1. Within your health trust how many patients are currently [within the past 6 months available] being treated for head and neck cancer (Squamous cell carcinoma)?**

Between 1<sup>st</sup> October 2017 – 31<sup>st</sup> March 2018, there were 107 patients currently being treated for head and neck cancer.

- 2. Of these patients how many are locally advanced and how many are recurrent and/or metastatic head and neck cancer patients?**

Locally advanced - 32

Recurrent metastatic – 48

- 3. Of the locally advanced/ recurrent or metastatic head and neck cancer patients how many are currently [within the past 6 months available]**

Please see data below for the period 1<sup>st</sup> October 2017 – 31<sup>st</sup> March 2018. Please be advised we are unable to differentiate between those who are locally advanced/recurrent or metastatic from our data systems therefore the data supplied below refers to ALL head and neck cancer patients.

Please note that the data below also includes patients receiving radiotherapy in combination with their chemo for the carboplatin and cisplatin totals below.

We are unable to provide data for radiotherapy alone as we are unable to differentiate the data between radiotherapy and chemo-radiotherapy; however we can confirm there were in total 62 radiology and chemo-radiology patients between the 1<sup>st</sup> October 2017 – 31<sup>st</sup> March 2018.

Carboplatin (only or in combination with 5-FU)	**
Cisplatin (only or in combination with 5-FU)	22
Cetuximab (Erbix) with/without chemotherapy	**
Cetuximab (Erbix) with radiotherapy	**

Docetaxel (Taxotere) - only or in combination with 5-FU	0
Fluorouracil (5FU)	0
Radiotherapy only	We do not hold this information
Other	11

Where the figures are fewer than 5, this has been denoted by \*\*. Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. Therefore under Section 40(2) of the Freedom of Information Act 2000, we will not be disclosing this information at this time. Section 40 is the exemption for personal information

**4. Does your health trust participate in any ongoing clinical trials for the treatment of head and neck cancer patients, if so how many patients are currently taking part in clinical trials?**

There are currently 7 Head & Neck cancer patient trials currently open with 75 patients recruited into these.

**5. Within your health trust how many patients are currently [within the past 6 months available] being drug treated for metastatic colorectal cancer? Of those patients please split by their drug treatment;**

Please see data below for the period 1<sup>st</sup> October 2017 – 31<sup>st</sup> March 2018.

NB. Some patients treated with two different lines of treatment within 6 month period so total number of patients less than the total of all the categories below as some fall in to two categories with different lines of treatment. Other only includes other anti-cancer treatment.

Total Patients	100
Cetuximab (Erbix) with/without chemotherapy	7
Panitumumab (Vectibix) with/without chemotherapy	8
Nivolumab (Opdivo) with/without chemotherapy	0
Chemotherapy + other mAb	**
Chemotherapy alone	85
Other	**

Where the figures are fewer than 5, this has been denoted by \*\*. Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of

the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. Therefore under Section 40(2) of the Freedom of Information Act 2000, we will not be disclosing this information at this time. Section 40 is the exemption for personal information

**6. Does your health trust participate in any ongoing clinical trials for the treatment of colorectal cancer patients, if so how many patients are currently taking part in clinical trials?**

University Hospital Bristol NHS Foundation Trust is currently has 5 colorectal studies open with 354 patients.

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Trust Secretary  
University Hospitals Bristol NHS Foundation Trust  
Trust Headquarters  
Marlborough Street  
Bristol  
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely,

██████████  
██████████